Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 20192019년 코로나바이러스 질병 치료에서 메틸프레드니솔론의 임상 효능 및 로피나비르/리토나비르와 아르비돌의 병용 사용Observational Study Published on 2021-07-012022-09-11 Journal: Journal of medical virology [Category] SARS, 임상, 치료제, [키워드] Admission Affiliated Hospital ARB Arbidol body temperature change clinical Clinical efficacy combined use coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients dose Efficacy examined hospital Hospital stay Laboratory Lopinavir Lopinavir/ritonavir medication Medicine Methylprednisolone Myocardial function Negative conversion no significant difference no significant differences nucleic acid Patient patients per day produced receiving recruited reduced renal Ritonavir School severe cases severe patients therapeutic efficacy Treatment university was used while Zhejiang [DOI] 10.1002/jmv.26798 PMC 바로가기 [Article Type] Observational Study
He-Jie-Shen-Shi Decoction as an Adjuvant Therapy on Severe Coronavirus Disease 2019: A Retrospective Cohort and Potential Mechanistic StudyPharmacology Published on 2021-06-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute respiratory distress acute respiratory distress syndrome adjuvant Analysis ARDS Bupleurum can be used CCL2 Chinese Clinical efficacy Clinical practice combination therapy component composed conducted coronavirus disease Coronavirus disease 2019 COVID-19 Cytoscape Decoction Effect endothelial Fever GeneCard Glycyrrhiza uralensis growth factor he-jie-shen-shi decoction IL1B Inflammatory response inheritance inhibiting viral replication involved KEGG Kyoto Ligand Lung injury Man MAPK MAPK signaling MAPK3 mechanism mechanisms Medicine monotherapy Necrosis Negative conversion network network pharmacology nine notable nucleic acid oxidative stress p53 pathway Pathways Patient Pharmacology Pinellia ternata Potential PPI predict Protein Protein–protein interaction PTGS2 receptor required Result retrospective cohort study screened Scutellaria baicalensis selected severe COVID-19 shown suggested syndrome System T cell receptor target TCMSP therapeutic therapy TNF Toll-like receptor Tongji Hospital TP53 Traditional Traditional Chinese medicine treat Vascular VEGF VEGFA Wuhan [DOI] 10.3389/fphar.2021.700498 PMC 바로가기 [Article Type] Pharmacology
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal StudyArticle Published on 2021-06-072022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] 16S rRNA Amplicon sequencing applied Asymptomatic Bacteroidetes changed COVID-19 determine Effect FB ratio Fecal sample Gastrointestinal symptom Gut gut microbiota healthy controls Infection intestinal longitudinal longitudinal analysis microbe Microbiome Mild Modifying Negative conversion Patient patients with asymptomatic phase profile reported respiratory infection respiratory symptoms reversion SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV2 selected significantly increased therapeutic Viral RNA was performed with COVID-19 [DOI] 10.3390/microorganisms9061237 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Gastrointestinal Infection Prolongs the Time to Recover From COVID-19Medicine Published on 2021-06-042022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] adverse effect age alimentary tract Antiviral treatment Clinical outcome COVID-19 epidemiological history fecal Gastrointestinal Gastrointestinal infection Hospitalization indicate infect Infection material median Negative conversion Patient patients with COVID-19 positive primary endpoint reported respiratory tract sample respiratory tract samples retrospective cohort study SARS-CoV-2 SARS-CoV-2 RNA secondary outcome Sex stool viral load subgroup analysis the patient time with COVID-19 [DOI] 10.3389/fmed.2021.683551 PMC 바로가기 [Article Type] Medicine
Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis–Manifested Severe DiseasePharmacology Published on 2021-05-262022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] administration adverse event AEs Analysis association benefit caution Clinical improvement Clinical practice Confidence intervals coronavirus coronavirus disease Corticosteroid Corticosteroids COVID-19 COVID-19 patient critically ill/pulmonary fibrosis manifested database dose Effect effect size Efficacy Egger’s test eligible evaluated Evidence fixed hospital Hospital stay Hospitalization ICU intensive care intervals mechanical ventilation Mortality Negative conversion outcome Patient pulmonary Random-effects models reduction in mortality risk reduction searched sensitivity analysis systemic Treatment UMBRELLA umbrella meta-analysis virus clearance [DOI] 10.3389/fphar.2021.670170 PMC 바로가기 [Article Type] Pharmacology
Efficacy and safety of Xuanfei Baidu granules for treating COVID-19 A protocol for systematic review and meta-analysis코로나19 치료를 위한 Xuanfei Baidu 과립의 효능 및 안전성 체계적인 검토 및 메타 분석을 위한 프로토콜 A4400 Published on 2021-05-212022-08-31 Journal: Medicine [Category] meta-analysis, SARS, 임상, 치료제, [키워드] Analysis average Baidu bias risk carried checked China Chinese clinical symptom Computed tomography Corona corona virus disease 2019 country COVID-19 COVID-19 diagnosis COVID-19 patient database Diagnosis disease effective Efficacy and safety evaluate evaluated evaluator Evidence extraction Granule Health Hospital stay include Infrastructure Intervention journal knowledge list lung management Meta Meta-analysis Negative conversion nucleic acid plan prevalent protocol Randomized controlled trials registration number registry released responsible review Science searched statistical systematic review technology Traditional Chinese medicine treating COVID-19 Treatment treatment of COVID-19 Trial Virus Disease Web website Wuhan Wuhan, China Xuanfei Baidu granule [DOI] 10.1097/MD.0000000000025653 PMC 바로가기 [Article Type] 4400
Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial무증상 및 경증 COVID-19 환자에 대한 nelfinavir의 효능 및 안전성: 다기관, 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-282022-09-10 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 1:1 Administered administration adverse event adverse events age all-cause mortality ALT Analysis anticipated Antigen antiviral efficacy AST Asymptomatic asymptomatic patients blinded blinded outcome assessment Blinding blood glucose body temperature both group both groups capture caused childbearing potential clearance clinical Clinical efficacy clinical examinations Clinical symptoms clinical trial clinical trials comparator Patients condition Consent contraceptive method Controlled clinical trial cough COVID-19 creatinine creatinine clearance dataset Day defervescence diabete diabetes diarrhea discretion dissemination distribution drug element enrolled enrolment evaluate event exclusion criteria exploratory Factor female patient Fever Frequency Glucose group hazard ratio Hemophiliac Hemorrhagic history HIV infection hospital hypersensitivity incidence incidence rate Inclusion inclusion and exclusion criteria inclusion criteria Infection Informed consent initial investigator investigator-initiated investigators Japan Japanese LAMP limit log-rank test male Mild mild COVID-19 patient Mild disease mixed-effects model multicenter Nasopharyngeal swab Negative conversion Negative PCR nelfinavir null hypothesis number objective Open-label outcome oxygen Oxygen administration p value parallel group parameter participant Patient patients with asymptomatic PCR PCR test Pneumonia power Pregnancy primary endpoint Primary outcome principal investigator Probability probability distribution protocol random randomization Randomized Randomized controlled trial Registered registry reported required respiratory tract rifampicin room air safety endpoint Saliva saliva samples Sample size SARS-CoV-2 SARS-CoV-2 vaccination secondary efficacy endpoint serious complication serum creatinine severity specimen Standard status study period Study protocol supplementary material survival survival function Symptom symptomatic symptomatic COVID-19 Symptomatic treatment the log-rank test Three times daily Treatment treatment for HIV treatment period Trial Trial registration two-sided Unsuitable Viral viral dynamics Viral load virus was determined website Withdrawal withdrawal of consent [DOI] 10.1186/s13063-021-05282-w PMC 바로가기 [Article Type] Letter
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis하이드록시클로로퀸 사용과 COVID-19의 진행 또는 예후: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-04-012022-09-11 Journal: Naunyn-Schmiedeberg's Archives of Pharmacology [Category] 치료제, [키워드] 95% CI Abstract acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antiviral activity benefit bioRxiv Chest CT clinical trials Cochrane Library coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated eligible Evidence exacerbated HCQ Hydroxychloroquine implicated in vitro inception Inclusion inclusion criteria item Meta-analysis Negative conversion no significant difference no statistical difference participant Patient Pneumonia Prognosis progressed progression RCT RCTs Reporting review robust RT-PCR SARS-CoV-2 screened searched severe acute respiratory syndrome Coronavirus significant difference ST group standard treatment Support systematic review title Treatment treatment for COVID-19 treatment of COVID-19 with COVID-19 [DOI] 10.1007/s00210-020-01964-5 PMC 바로가기 [Article Type] Meta-Analysis
Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in DaeguArticle Published on 2021-03-012023-07-06 Journal: Allergy [Category] SARS, [키워드] Asthma COVID-19 Negative conversion Prevalence risk factor SARS-CoV-2 [DOI] 10.1111/all.14609 PMC 바로가기
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019경증에서 중등도의 코로나바이러스 질환 환자의 바이러스 제거 및 임상 개선을 위한 로피나비르-리토나비르 대 하이드록시클로로퀸 2019Comparative Study Published on 2021-03-012022-09-11 Journal: The Korean journal of internal medicine [Category] SARS, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted hazard ratio age baseline Clinical improvement clinical response clinical responses comparable coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients duration of symptom Efficacy Follow-up Hydroxychloroquine hydroxychloroquine treatment hyperbilirubinemia less Lopinavir Lopinavir-ritonavir lymphopenia median men Mild mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 Negative conversion no significant difference outcome oxygen oxygen support Patient patients patients with COVID-19 randomized, controlled trials required retrospective cohort study Ritonavir severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significant difference significantly shorter single center time treated Treatment viral clearance Viral RNA Virological were assessed were excluded [DOI] 10.3904/kjim.2020.224 PMC 바로가기 [Article Type] Comparative Study